ClinicalTrials.gg
RecruitingNCT05688488Updated May 6, 2023

Clinical Study of Curcumin in Preventing Postoperative Adhesion of Bilateral Vocal Cords

A Phase 1/2 interventional study of Curcumin and Mitomycin-C in Glottic Web of Larynx, Laryngeal Stenosis and Glottic Carcinoma, sponsored by Eye & ENT Hospital of Fudan University. Recruiting at 1 site in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2023-05-06.

Sponsored by Eye & ENT Hospital of Fudan University · Phase 1/2, Interventional, and Prevention

From the registry’s dates

  • Primary completion was expected by Dec 2025, 10 months ago, but the record still lists the study as recruiting.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
100
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Study summary

To provide a novel therapy idea and method to solve the clinical problem of postoperative adhesion of bilateral vocal cords, patients enrolled in this study will be applied with curcumin on both wound sites of bilateral vocal cords after the surgery on the bilateral vocal cord endoscopically.

02

Conditions studied

  • Glottic Web of Larynx
  • Laryngeal Stenosis
  • Glottic Carcinoma
  • Laryngeal Leucoplakia
  • Laryngeal Polyp
  • Laryngeal Papilloma

Keywords

  • Curcumin
03

In context

Lead sponsor

Eye & ENT Hospital of Fudan University is the lead sponsor of 127 studies on the registry; 71 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Patients with bilateral vocal cord diseases who are going to undergo resection of bilateral vocal cord lesions endoscopically.
  2. Patients with bilateral vocal cord adhesion who are going to undergo incision of bilateral vocal cord adhesion endoscopically.

Exclusion criteria

Exclusion Criteria:

  1. Patients with other laryngeal diseases.
  2. Patients with cardiac and pulmonary insufficiency.
  3. Patients unable to cooperate with the follow-up on time after surgery.
  4. Patients who refuse to sign the after notification.
  5. Patients who have a severe allergic disease or allergic history to a variety of drugs.
  6. Other circumstances that are not appropriate to be included in the clinical trial.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Outcomes assessor)
Enrollment
100 participants (estimated)

Study arms

  • Experimental
    Curcumin

    Drug: Curcumin

  • Active comparator
    Mitomycin

    Drug: Mitomycin-C

Interventions

  • Curcumin was applied to both wound sites of bilateral vocal cords. After evenly applied, gently massage the applied site for 3-5 minutes until the drug was fully absorbed.

  • Mitomycin-C was applied to both wound sites of bilateral vocal cords. After evenly applied, gently massage the applied site for 3-5 minutes until the drug was fully absorbed.

06

What researchers measure

Primary outcomes

  1. Number of participants with laryngeal web formation as assessed by videolaryngoscope

    All participants received the videolaryngoscope every month post-surgery, and a laryngeal web is defined as a visible adhesion whose length reached 1 mm or greater.

    Time frame: 1 year postsurgery

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for May 2023; primary completion for Dec 2025, 31 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 28, 2022
First posted
Jan 18, 2023
StartEst.
May 5, 2023
Primary completionEst.
Dec 31, 2025
CompletionEst.
Dec 31, 2026
Last update
May 6, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 6, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05688488
Responsible party
Sponsor
First posted
Jan 18, 2023
Start date
May 5, 2023 (estimated)
Primary completion
Dec 31, 2025 (estimated)
Completion
Dec 31, 2026 (estimated)
Last update
May 6, 2023

Study contacts

Jian Chen, Ph.D
Contact
chenjent@qq.com
+8621-64377134
Haitao Wu, Ph.D
Contact
eentwuhaitao@163.com
+8621-64377134

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Curcumin

Start the discussion